Determination of Metabolomic Profile Differences in Possible Sarcopenia Accompanying Fibromyalgia Syndrome in Women

Determination of Metabolomic Profile Differences in Possible Sarcopenia Accompanying Fibromyalgia Syndrome in Women

The goal of this observational study is to determine the serum metabolome profile differences in the presence of possible sarcopenia in patients with fibromyalgia and to compare them with healthy individuals. In this way, it is aimed to contribute to the knowledge about the pathophysiology, diagnosis and treatment of these diseases.The main questions it aims to answer are:

• Is there a difference in blood metabolite levels and metabolic pathways in fibromyalgia syndrome and possible sarcopenia accompanying fibromyalgia syndrome?
• Based on these identified differences, can biomarkers be determined for these diseases?

After being informed about study and potential risks, all patient giving written informed consent will undergo screening period determine eligibility for study entry. Participants will be divided into three groups: those with fibromyalgia syndrome and probable sarcopenia, those with fibromyalgia syndrome and no probable sarcopenia, and healthy people. Presence of probable sarcopenia and sarcopenia will be determined by using SARC-F scale, hand grip strength measurement with hand dynamometer, muscle mass measurement with Bioimpedance Analysis, anthropometric measurement, walking speed measurement in patients with fibromyalgia diagnosis.The serum metabolome profiles of the three groups will be compared.

Inclusion Criteria:

1. Being between 18-60 years old
2. Being diagnosed with Fibromyalgia according to ACR 2016 diagnostic criteria
3. Having agreed to participate in the study
4. Healthy controls
5. Being a woman

Exclusion Criteria:

1. Those who cannot take command due to cognitive dysfunction
2. Pregnancy
3. Those with severe cardiac disease, COPD, malignancy, neuromuscular disease, inflammatory rheumatic disease and organ failure
4. Those with orthopedic disorders that may cause limitation in joint range of motion and/or loss of motor muscle strength
5. Patients using systemic glucocorticoid, ACE-I / ARB, statin, sulfonylurea, allopurinol